AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05546203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized exercise program
Description: The standardized exercise program included stretching and pilates exercises for core stabilization. All exercises were supervised by the same physiotherapist whom certificated by The Australian Physiotherapy and Pilates Institute (APPI). Pilates exercises were selected from APPI's mat-work exercises and performed in accordance with APPI principles. In addition, patients performed stretching exercises for 5 days a week and pilates exercises for 3 days a week at home.
Study NCT02999438 — intervention group
Intervention type: DEVICE
Intervention: Actigraph to check activity levels at home
Study NCT03622918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colistin and rifampin combination therapy
Description: Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
Study NCT03622918 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: colistin monotherapy
Description: . Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment wil be determined through discussion by pulmonology and infection specialist .
Study NCT04050202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) Intervention
Description: ABC is a 10 session, home-based, dyadic therapy that is delivered by a trained professional. The sessions focus on improving the parent-child relationship and children's biological and behavioral responses to stress.
Study NCT03030976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
Study NCT03030976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR-T cells
Description: A 2nd CAR, CD19 as target protein, 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences. Patients infused with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity to treatment of SLE. The dose is 1E6\~1E7 CD19-CAR positive T cells. The cells infusion process may last for 30 min.
Study NCT03846518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyrax
Description: Rapid maxillary expansion using the Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars.The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
Study NCT03846518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mini Hyrax
Description: Rapid maxillary expansion using the mini Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars. The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
Study NCT01060280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education on active management
Description: Routine clinical practice plus education on active management.
Study NCT01060280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group GDS physiotherapy
Description: Routine clinical practice (which will be substituted by Group GDS) plus education on active management.
Study NCT01060280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual GDS physiotherapy
Description: Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.
Study NCT01501877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The intervention is based on Acceptance and Commitment Therapy and will be tailored to smokers with Type 2 diabetes.
Study NCT01501877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard smoking cessation intervention
Description: Standard smoking cessation intervention based on clinical practice guidelines.
Study NCT00481091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral
Study NCT02405442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered via subcutaneous (SC) injection
Study NCT02405442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Andecaliximab
Description: Andecaliximab administered via subcutaneous (SC) injection
Study NCT02405442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match andecaliximab administered via SC injection
Study NCT02405442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match andecaliximab administered via SC injection
Study NCT01290913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab is an antibody that helps decrease allergic responses in the body
Study NCT01563653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4 diagnostic tests for surgical success
Description: Q-tip test, Bonney maneuver, TVT maneuver, clip strip test
Study NCT00856232 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Air
Description: Compressed medical air
Study NCT00856232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Medical Oxygen
Study NCT03565328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
Study NCT05591313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LI-40
Description: Participants were asked to complete a volume-matched light-intensity exercise for 30-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
Study NCT05591313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-30
Description: Participants were asked to complete a volume-matched moderate-intensity exercise for 20-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
Study NCT05591313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HI-16
Description: Participants were asked to complete a volume-matched high-intensity exercise for 16-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
Study NCT02730780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low-Salt Diet
Description: The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.
Study NCT02730780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-Salt Diet
Description: The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.
Study NCT02384434 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: THOR Laser System for Low Level Laser Therapy (LLLT)
Description: Non-invasive, a cold laser output treatment.
Study NCT01676779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell therapy
Description: Dendritic cell therapy IV and ID
Study NCT01311024 — intervention group
Intervention type: BIOLOGICAL
Intervention: PCV GSK1024850A
Description: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
Study NCT01311024 — intervention group
Intervention type: BIOLOGICAL
Intervention: hepatitis B vaccine or hepatitis A vaccine
Description: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
Study NCT05486624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki, one of the complementary treatments, was applied by touching the chakra areas of the body by hand.
Study NCT03830892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 15 watts, 10 mg nicotine
Description: E-cigarette paired with low nicotine, low device power
Study NCT03830892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 15 watts, 30 mg nicotine
Description: E-cigarette paired with low nicotine, low device power
Study NCT03830892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 30 watts, 10 mg nicotine
Description: E-cigarette paired with low nicotine, low device power
Study NCT03830892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 30 watts, 30 mg nicotine
Description: E-cigarette paired with low nicotine, low device power
Study NCT03830892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Own Brand Session - E-cigarette
Description: E-cigarette paired with own brand liquid and preferred power
Study NCT04181853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: aerobic exercise
Study NCT01855932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Supported
Description: All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
Study NCT04795609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).
Description: Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).~1. Trunk control.~2. Orthostatism.~3. Walk training.~4. Aerobic exercises.~5. Muscle strengthening.
Study NCT03382548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reducing Antibiotics treatment duration
Description: Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
Study NCT03830892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Own Brand Session - E-cigarette/Cigarette
Description: Own brand cigarette OR E-cigarette paired with own brand liquid and preferred power
Study NCT03382548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Antibiotics treatment duration
Description: Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.
Study NCT04510077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartQuit Smoking and Tobacco Cessation Program
Description: Use SmartQuit program
Study NCT04510077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05250245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine Tartrate 4 MG
Description: Tolterodine is actively being used in the treatment of over active bladder symptoms today
Study NCT05250245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure therapy (CPAP)
Description: The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy
Study NCT04254770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ADA approved Manual Toothbrush
Description: ADA approved Manual Toothbrush
Study NCT04254770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marketed Power Toothbrush
Description: Marketed Power Toothbrush
Study NCT01783678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT04661579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Vaccine RTS,S/AS01E
Description: RTS,S/AS01E vaccine 0.5 mL, containing 25 μg protein comprising circumsporozoite protein (CS) and hepatitis B surface antigen (RTS,S), 25 μg monophosphoryl lipid (AMPL), 25 μg Quillaja saponaria 21 (QS21) in a liposomal formulation) for the first two immunizations. One-fifth dose RTS,S/AS01E vaccine was used for the third immunization.
Study NCT04661579 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Abhayrab rabies vaccine
Description: Abhayrab rabies vaccine, 0.5 mL, contains 2.5 IU rabies antigen.
Study NCT04661579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/Pip)
Description: Dihydroartemisinin (120 mg or 160 mg based on weight) and piperaquine tetraphosphate (960 mg or 1280 mg based on weight) mg) administered once a day for 3 days.~DHA/Pip is a long acting anti-malarial used to clear asexual stage and young gametocyte parasites.
Study NCT04661579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA/Pip)
Description: Dihydroartemisinin (120 mg or 160 mg based on weight) and piperaquine tetraphosphate (960 mg or 1280 mg based on weight) mg) administered once a day for 3 days.~DHA/Pip is a long acting anti-malarial used to clear asexual stage and young gametocyte parasites.
Study NCT04661579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether / Lumefantrine
Description: Artemether (80 mg) and lumefantrine (480 mg) administered twice a day for 3 days.~Coartem is a short-acting artemisinin combination therapy used to provide clearance of blood stage parasites in order to establish a clean baseline for determination of vaccine efficacy.
Study NCT04661579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemether / Lumefantrine
Description: Artemether (80 mg) and lumefantrine (480 mg) administered twice a day for 3 days.~Coartem is a short-acting artemisinin combination therapy used to provide clearance of blood stage parasites in order to establish a clean baseline for determination of vaccine efficacy.
Study NCT04661579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: One dose of 15 mg primaquine. Low dose primaquine (LD PQ) is used to clear mature gametocytes of P. falciparum.
Study NCT04661579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Primaquine
Description: One dose of 15 mg primaquine. Low dose primaquine (LD PQ) is used to clear mature gametocytes of P. falciparum.
Study NCT00951197 — intervention group
Intervention type: OTHER
Intervention: Neuroimaging
Description: Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
Study NCT03799302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIC Coaching
Description: Sites receiving consultation to implement either TFCO or MDFT will also receive consultation on their implementation fidelity as measured and tracked by the SIC.
Study NCT01863836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Study NCT01863836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial EBUS-guided biopsy
Study NCT01863836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial EBUS-guided biopsy
Study NCT03263702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computational Mapping Algorithm
Description: This software enables high resolution temporospatial mapping of atria for the identification of drivers of AF. CMA receives data from standard of care, commercially available 3D Mapping Systems (St. Jude Ensite System) and catheters and processes the data in a unique way. Electrogram and anatomy data are fed from the commercially available 3D Mapping System to an adjacent laptop computer, via an Ethernet connection, that is running CMA. CMA then processes the electrogram data and generates a map of where the potential AF driver domains are located and superimposes those potential AF driver domain targets onto the 3D geometry of the anatomy (provided by the 3D mapping system).
Study NCT02117622 — intervention group
Intervention type: DRUG
Intervention: insulin degludec
Description: Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study
Study NCT04050280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
Description: Induction:~G-CSF 300 mcg subcutaneously daily on days 0-5.~Cladribine 5 mg/m2 in normal saline given intravenously over 2 hours daily on days 1-5.~Cytarabine 2000 mg/m2 in normal saline given intravenously over 4 hours daily on days 1-5.~Gemtuzumab ozogamicin 3 mg/m2 intravenously over 2 hours on days 1 and 4, prior to cladribine and cytarabine.~Consolidation:~If CRMRD-, CR or CRi is confirmed by bone marrow biopsy and aspirate after induction chemotherapy, patients may receive one cycle of consolidation chemotherapy (at the discretion of the investigator) with the same CLAG-GO regimen at the same doses given for induction. In addition, the investigator has the option of giving CLAG alone without GO if there is concern for increased risk of sinusoidal obstruction syndrome.~Patients who remain in CRMRD-, CR or CRi after consolidation chemotherapy may receive up to eight infusions of GO 2 mg/m2 approximately every 28 days.
Study NCT04316819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed Promise Demonstration Benefits
Description: Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
Study NCT01350193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manuka Honey
Description: The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
Study NCT01350193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Irrigation
Description: The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
Study NCT03745885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Administered SC in the Supaglutide arms.
Study NCT03745885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.